For Vinorelbine treatment to show clinical benefit, it is reasonable to assume that the BRAF mutation population needs to be dominant in the tumor and resulted in a measurable gene expression pattern, only in this scenario the drug will likely be effective to kill the dominant population of the tumor cells. Here, BRAF is linked to neoplasm.